Lexicon Pharma (LXRX) Announces Sotagliflozin Phase 3 in T1D Met Primary Endpoint
- Nasdaq, S&P tumble as Netflix, chip stocks drag; AmEx boosts Dow
- Sony/Apollo bid for Paramount could be worth as much as $29 billion - Source
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Wall St indexes split, Treasuries dip amid earnings, geopolitical crosscurrents
- Gold prices rally past $2,400 on reports of Israel strikes on Iran
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Jabil falls after placing CEO on paid leave amid internal investigation
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- Ibotta (IBTA) Prices 6.56M Share IPO at $88/sh
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
Wedbush Raise Lexicon Pharmaceuticals (LXRX) PT to $33 as Primary Endpoint Reached
September 9, 2016 11:57 AM EDTWedbush analyst Liana Moussatos reiterated an Outperform rating and boosted her price target on Lexicon Pharmaceuticals (NASDAQ: LXRX) to $33.00 after sotagliflozin achieves its primary endpoint in first T1D phase III trial.
Moussatos commented, "With inTandem1 for Type 1 diabetes (T1D)... More
Needham & Company Positive on Lexicon Pharma (LXRX) Following Sotagliflozin Phase 3 Data; Affirms at 'Buy'
September 9, 2016 11:22 AM EDTNeedham & Company affirms Lexicon Pharma (Nasdaq: LXRX) with a Buy rating and $21 price target after Lexicon announced that the pivotal inTandem1 Phase 3 clinical trial of sotagliflozin met its primary endpoint,... More